Breast Cancer | Specialty

Dr. Mitri on Neratinib and Pertuzumab in HER2-Amplified Breast Cancer

June 19th 2018

Zahi Mitri, MD, MS, assistant professor of medicine, Oregon Health and Science University, discusses the use of neratinib (Nerlynx) and pertuzumab (Perjeta) in patients with HER2-amplified breast cancer.

Dr. McCann on Prognosis for Patients With HER2-Positive Breast Cancer

June 16th 2018

Kelly McCann, MD, PhD, a medical oncologist in the Breast Cancer Research Group at the University of California, Los Angeles, discusses the current prognosis for patients with HER2-positive breast cancer.

Patients Aged

June 13th 2018

Patients younger than 65 years experienced net cancer costs that were higher for breast, colorectal, lung, and prostate cancer compared with patients who were 65 years and older.

Dr. Dent Discusses the LOTUS Trial in Triple-Negative Breast Cancer

June 12th 2018

Rebecca Dent, MD, senior consultant, National Cancer Center, Singapore, discusses the results of the LOTUS trial in patients with triple-negative breast cancer.

Newman Discusses De-escalating Breast Cancer Surgery

June 11th 2018

Lisa A. Newman, MD, discusses de-escalation strategies emerging in breast cancer surgery.

Expert Recaps Radiation Refinements in Breast Cancer

June 8th 2018

Eleanor M. Walker, MD, discusses advances in radiation therapy in breast cancer and the rationale for hypofractionated scheduling.

FDA Grants Talazoparib Priority Review for BRCA+ Breast Cancer

June 7th 2018

The FDA has granted a priority review to a new drug application for talazoparib for the treatment of patients with germline BRCA mutation–positive, HER2-negative locally advanced or metastatic breast cancer.

Niraparib/Pembrolizumab Combo Active in Relapsed, Progressive TNBC

June 6th 2018

Half of patients with metastatic triple-negative breast cancer achieved disease control when treated with the combination of niraparib (Zejula) and pembrolizumab (Keytruda).

Dr. Naik on Surgical Approaches in Patients With Breast Cancer

June 5th 2018

Arpana M. Naik, MD, associate professor of surgery, Division of Surgical Oncology, School of Medicine, Oregeon Health and Science University, discusses surgical approaches in the treatment of patients with breast cancer.

Dr. Slamon on the Phase III Results of MONALEESA-3 Trial in HR+/HER2- Breast Cancer

June 4th 2018

Dennis J. Slamon, MD, PhD, director, Clinical/Translational Research, Revlon/University of California, Los Angeles (UCLA) Women's Cancer Research Program, Jonsson Comprehensive Cancer Center, UCLA, discusses findings of the phase III MONALEESA-3 trial evaluating ribociclib (Kisqali) plus fulvestrant (Faslodex) in postmenopausal women with hormone receptor (HR)-positive, HER2-negative advanced breast cancer.

Early OS Data Support Phase III Trial With AKT Inhibitor Ipatasertib for TNBC

June 4th 2018

First-line treatment with the oral AKT inhibitor ipatasertib shows a promising trend toward improving overall survival when added to paclitaxel for the treatment of locally advanced or metastatic triple-negative breast cancer.

Ribociclib Prolongs PFS With Fulvestrant in First- or Second-Line HR-Positive, HER2-Negative Advanced Breast Cancer

June 3rd 2018

Adding the CDK4/6 inhibitor ribociclib to fulvestrant significantly prolonged progression-free survival in postmenopausal women with hormone receptor-positive, HER2-negative advanced breast cancer who received no or 1 prior line of therapy.

Endocrine Therapy Alone Is Sufficient in HR+/HER2- Breast Cancer With Intermediate Recurrence Score

June 3rd 2018

Adjuvant endocrine therapy alone is noninferior to adjuvant chemoendocrine therapy in patients with hormone receptor–positive, HER2-negative, node-negative early-stage breast cancer.

Matched Targeted Therapy Extends Survival in Advanced Hard-to-Treat Cancers

June 2nd 2018

Personalized therapy based on tumor molecular profiling resulted in improved overall survival for patients with advanced, hard-to-treat cancers.

Only Modest Benefit Seen With Taselisib in PIK3CA-Mutant Breast Cancer

June 2nd 2018

Treatment with taselisib in combination with fulvestrant provided a modest progression-free survival benefit of 2 months compared with fulvestrant alone in patients with estrogen receptor–positive, PIK3CA-mutant locally advanced or metastatic breast cancer

Practice Changes for Use of Immunotherapy in NSCLC: Q&A

June 2nd 2018

Using Immunotherapy Beyond Progression in NSCLC

June 2nd 2018

Optimizing Immunotherapy in the NSCLC Treatment Paradigm

June 2nd 2018

Tumor Mutational Burden in NSCLC: Should it be Routine?

June 2nd 2018

Impact of Data on the Real-Life Treatment of NSCLC

June 2nd 2018